Background
==========

Heart failure (HF) is often accompanied by disturbances of breathing during sleep (SDB, sleep-disordered breathing). The frequency of obstructive sleep apnea (OSA) in a population of patients with HF is estimated as 11--43% and central sleep apnea (CSA) as 28--40% \[[@b1-medscimonit-22-2989]--[@b4-medscimonit-22-2989]\]. Obstructive sleep apnea, mainly associated with hypertension and cardiac arrhythmias, dominates in milder forms of HF, whereas CSA of the Cheyne-Stokes type of respiration (CSR) is typical for advanced HF \[[@b5-medscimonit-22-2989]\].

The main pathophysiological phenomena related to CSR are: chronic hyperventilation, hypocapnia, and hypersensitivity to carbon dioxide partial pressure \[[@b6-medscimonit-22-2989]--[@b9-medscimonit-22-2989]\]. Cheyne-Stokes respiration is usually associated with significant myocardial impairment and constitutes an independent negative prognostic factor \[[@b10-medscimonit-22-2989]\]. There are also opinions that it is the compensation mechanism \[[@b11-medscimonit-22-2989],[@b12-medscimonit-22-2989]\]. However, there is no doubt that the recognition of CSR in patients with HF has important therapeutic implications. In recent years, many studies confirmed the beneficial effect of SDB-specific treatment on cardiac function and quality of life \[[@b13-medscimonit-22-2989]--[@b17-medscimonit-22-2989]\]. Nevertheless, recent reports have called into question the benefits from adaptive servo-ventilation, which is a new method of non-invasive ventilation, on the cardiovascular system of patients with CSR and advanced HF \[[@b18-medscimonit-22-2989]\]. Despite these controversies, it is still reasonable to look for indicators useful in identifying patients with SDB.

Identification of patients at high risk of CSR is not easy. The symptoms of CSR are usually masked by complaints typical of HF. Moreover, the recommendations on how to select patients to screen for CSR are still not clearly established. At the same time, the availability of polysomnography is limited. Thus, there is still a need for identification of non-invasive predictors of the occurrence of CSR, which will help to optimize the process of diagnosis.

Therefore, the aim of this study was to evaluate the relationship between CSA/CSR and other clinical features of HF, with particular emphasis on cardiovascular hemodynamics, and to identify those that may be useful in predicting the occurrence of CSR in this population.

Material and Methods
====================

Study group
-----------

The study was designed and implemented as a prospective clinical trial. Consecutive patients with systolic HF (ischemic and non-ischemic) were recruited. The inclusion criteria were: 1) HF diagnosed at least 3 months before the study, with a left ventricular ejection fraction (LVEF) assessed by echocardiography at ≤45%; 2) stable condition, with the severity of clinical symptoms according to NYHA class I--III; and 3) optimal medical therapy for at least 1 month. The exclusion criteria were: 1) HF deterioration; 2) HF as a result of primary valvular defect; 3) acute coronary syndrome in the last 6 months; 4) revascularization treatment; 5) myocarditis; 6) pulmonary embolism; 7) cerebrovascular event or transient ischemic attack (TIA); 8) implanted cardiac resynchronization device in the last 6 months; 9) chronic obstructive pulmonary disease (COPD) with FEV~1~ \<50%; and 10) respiratory failure (PaO~2~ \<60 mmHg and/or PaCO~2~ \>45 mmHg).

The study was conducted according to the Good Clinical Practice guidelines and the Declaration of Helsinki, with the approval of the local ethics committee. Each patient provided written informed consent to participate in the study. The recruited patients were examined with polygraphic test, and echocardiography and non-invasive assessment of hemodynamic parameters by means of ICG were performed.

Polygraphy test
---------------

Sleep-disordered breathing in all patients was diagnosed using the polygraphy system (Embletta, Embla, The Netherlands). During the examination, the following features were recorded: the flow of air through the upper airway, breathing movements of chest and abdomen, blood arterial oxygen saturation, pulse rate, snoring, and body position. The analysis was performed automatically using standard software (Somnologica for Embletta, Embla, The Netherlands), then verified manually.

Sleep-disordered breathing was defined according to the criteria of the American Academy of Sleep Medicine \[[@b19-medscimonit-22-2989]\]. Apnea was diagnosed when the amplitude of the flow of air through airways dropped to ≤10% and an episode of respiratory arrest lasted at least 10 seconds. Hypopnea was diagnosed when there were at least 10 seconds of airflow reduction in the respiratory tracts to ≤70%, combined with decrease in saturation of at least 4%. Apneas were defined as obstructive or central, depending on the presence or absence of breathing movements of the chest and abdomen. Breathing disorders during sleep were ultimately classified as: central, when \>50% of episodes of loss/reduction of air flow through the respiratory tracts were of central origin; or obstructive, when obstructive episodes dominated (they accounted for \>50% of all episodes). The level of respiratory disorders was established by the number of indicators of apnea and hypopnea per hour of sleep (AHI, apnea/hypopnea index): mild form, AHI ≥5 and \<15; moderate form, ≥15 and ≤30 episodes per hour; and severe form, \>30 \[[@b20-medscimonit-22-2989]\].

Cheyne-Stokes respiration was diagnosed when there were at least 3 consecutive cycles of respiration track with amplitude in the form of crescendo-decrescendo with central apnea or hypopnea, and at least 1 of the following conditions: 1) central AHI ≥5; or 2) cyclic change of crescendo-decrescendo lasting at least 10 minutes. Oxygen desaturation index (ODI) was defined as number of saturation drops by at least 4% per hour of sleep.

Echocardiographic studies
-------------------------

All patients underwent echocardiographic evaluation with the Vivid 7 Dimension system (GE Healthcare, USA) in a standard manner \[[@b21-medscimonit-22-2989],[@b22-medscimonit-22-2989]\]. Left ventricle (LV) function was assessed by measuring left ventricular ejection fraction (LVEF) according to Simpson's rule. The following parameters were obtained from the parasternal long axis view in the 2-dimensional presentation: left ventricular end-diastolic diameter (LVDd), left atrium dimension (LA), right ventricular end-diastolic diameter (RVDd) and intraventricular septum in diastole thickness (IVSd), and LV posterior wall thickness in diastole (PVd). Cardiac output (CO) was calculated by multiplying heart rate (HR) by LV stroke volume, which was determined from the product of velocity time integral through the outflow tract of the left ventricle and surface area of the LV outflow tract. The evaluation of E/e (defined as the ratio of the maximum velocity of early flow by mitral valve to early diastolic mitral annulus velocity in tissue Doppler) was also calculated.

Non-invasive monitoring of hemodynamic parameters by impedance cardiography
---------------------------------------------------------------------------

A non-invasive assessment of hemodynamic parameters by ICG (Niccomo, Medis, Germany) was performed during a 10-minute test in horizontal position, after not less than 10 minutes of rest. The measurements of HR, stroke index (SI), cardiac index (CI), systemic vascular resistance index (SVRI), and thoracic fluid content (TFC) were carried out with beat-to-beat method. Only arm systolic and diastolic blood pressure (SBP/DBP) measurement was performed (automatically) at 2-minute intervals. The parameters recorded in the 10^th^ minute of recording were used for the analysis.

Statistical methods
-------------------

The statistical analysis was performed using Statistica v.10 software (StatSoft, Inc., USA). The normality of data distribution was assessed using the Shapiro-Wilk test. Results are expressed as mean values and standard deviations (SD) for quantitative variables and frequencies and percentages for qualitative variables. We performed comparative analysis of 2 subgroups: patients with significant CSR (AHI ≥15/h) and patients with no significant CSR (AHI \<15/h).

Comparisons for quantitative variables were performed using *t* tests for variables of normal distribution and non-parametric tests (Mann-Whitney U test) for variables of non-normal distribution. In case of ordinal variables, the Mann-Whitney U test was used, and for nominal variables we used the chi-square/V-square/chi-square test with a Yatesav amendment (depending on the numbers expected in subgroups). Then, the most representative nominal variables differentiating the 2 subgroups were tested as the predictors of significant CSR with use of logistic regression models (univariable and multivariable). Results with p\<0.05 were considered statistically significant.

Results
=======

The study included 161 patients with basic characteristics as presented in [Table 1](#t1-medscimonit-22-2989){ref-type="table"}. Almost one-third of the subjects presented NYHA class III and permanent atrial fibrillation (AF) occurred in almost one-third of them. More than half of the patients (55.3%) presented LVEF\<35%. Forty-one patients (25.5%) were free from SDB, 47 (29.2%) had OSA, and 73 (45.3%) had CSA of Cheyne-Stokes type ([Figure 1](#f1-medscimonit-22-2989){ref-type="fig"}). Moderate and severe forms of CSR were found in 51 patients (31.7%).

Comparison of groups in terms of basic clinical parameters
----------------------------------------------------------

Comparative analysis revealed significantly greater severity of clinical symptoms (NYHA classification), higher prevalence of AF and implanted ICDs, lower SBP, and more frequent use of diuretics in patients with significant CSR ([Table 2](#t2-medscimonit-22-2989){ref-type="table"}, [Figure 2](#f2-medscimonit-22-2989){ref-type="fig"}).

Comparison of groups in polygraphy tests
----------------------------------------

In patients with significant CSR, as compared to the rest, the desaturation index (ODI) was significantly higher, and the average desaturation and the minimum saturation were lower ([Table 3](#t3-medscimonit-22-2989){ref-type="table"}).

Comparison of groups within echocardiographic studies
-----------------------------------------------------

Patients with important CSR in comparison to other patients had statistically significantly lower LVEF, larger dimensions of left and right ventricle and left atrium, and higher E/e' index ([Table 4](#t4-medscimonit-22-2989){ref-type="table"}).

Comparison of groups within hemodynamic assessment using impedance cardiography
-------------------------------------------------------------------------------

Patients with moderate and severe respiratory disorder of CSR type presented significantly lower SI and CI, higher SVRI, and higher HR ([Table 5](#t5-medscimonit-22-2989){ref-type="table"}).

Predictors of the presence of significant CSR
---------------------------------------------

In the univariate regression analysis, advanced NYHA class, permanent AF, right ventricular enlargement, LVEF \<35%, E/e' \>15, and SI \<35 ml/m^2^ proved to be predictors of presence of significant CSR ([Table 6](#t6-medscimonit-22-2989){ref-type="table"}). However, only NYHA class turned out to be an independent predictor.

Discussion
==========

Our results show wide prevalence of SDB in patients with systolic HF, despite optimal drug therapy. It appears that this problem is probably not adequately appreciated in this population. Sleep apnea is rarely recognized and frequently remains untreated. The insufficient awareness of the role of SDB in the pathogenesis of HF still plays an important role. However, the limited availability of diagnostic tools also is important. Therefore, a search for simple diagnostic parameters that increase the ability to identify patients with severe CSR can provide clinical benefits. We identified some prognostic variables, including those related with anamnesis (e.g., NYHA class and atrial fibrillation), heart morphology, and hemodynamics. Our results confirm the correlation between CSA and more advanced cardiovascular dysfunction.

Clinical characteristics of the population
------------------------------------------

Demographic profile and medical history of the recruited patients were similar to those of participants of other studies, concerning SDB and HF \[[@b1-medscimonit-22-2989]--[@b3-medscimonit-22-2989],[@b23-medscimonit-22-2989]\]. We confirmed wide dissemination of unrecognized SDB in patients with systolic HF, despite optimal drug therapy. Significant SDB (AHI ≥15/h) occurred in 44.7% of patients and more than twice as many patients had significant CSA than had OSA. Our data are similar to those presented by Oldenburg et al. \[[@b2-medscimonit-22-2989]\], who diagnosed SDB in 76% of 700 patients with HF (LVEF ≤40%), also with a higher proportion of CSA. Likewise, other authors reported similar frequencies of CSA \[[@b1-medscimonit-22-2989],[@b3-medscimonit-22-2989],[@b23-medscimonit-22-2989]\].

Central sleep apnea, clinical state, and co-existing diseases
-------------------------------------------------------------

Our results confirm that CSR is strongly associated with advanced HF. Features indirectly characterizing the severity of HF (advanced NYHA class, lower SBP, a greater need for diuretics, and a proportion of ICD implantations) corresponded with the occurrence of significant CSA/CSR. The obtained observations are compatible with the results of Oldenburg et al. \[[@b2-medscimonit-22-2989]\], who compared patients with CSA to those with OSA. Patients with CSA had significantly lower SBP and DBP, as well as a greater severity of symptoms according to NYHA. Javaheri et al. \[[@b1-medscimonit-22-2989]\] also observed lower values of DBP in patients with CSA. However, some studies did not confirm the correlation of CSR with NYHA class \[[@b3-medscimonit-22-2989],[@b24-medscimonit-22-2989]\].

The present study showed a strong relationship between CSR and AF. It confirms that CSA/CSR is etiologically associated with this form of arrhythmia. In a study of more than 2900 older men, a strong relationship of CSA with AF was demonstrated, and OSA was more associated with ventricular arrhythmia (bigeminy, trigeminy, and non-sustained ventricular tachycardia) \[[@b25-medscimonit-22-2989]\]. Another study revealed that, even in the absence of HF, AF is very strongly associated with CSA \[[@b26-medscimonit-22-2989]\]. Sin et al. \[[@b23-medscimonit-22-2989]\] and Schulz et al. \[[@b3-medscimonit-22-2989]\] also showed a higher incidence of AF in patients with CSA. It seems that the pathophysiological backgrounds of arrhythmia in OSA and CSA are different. OSA can lead to the occurrence of AF as a result of the dysfunction of autonomic system and increased atrial dimensions and pressure. The risk of ventricular arrhythmias related to OSA appears to result primarily from hypoxia \[[@b1-medscimonit-22-2989],[@b27-medscimonit-22-2989],[@b28-medscimonit-22-2989]\]. In contrast, CSR supraventricular and ventricular arrhythmias are *a priori* associated with a significant impairment of myocardial function, and to a lesser extent result from the disordered breathing.

Central sleep apnea and the function of cardiovascular system
-------------------------------------------------------------

The results of our study show that the presence of CSR is associated with worse hemodynamic and morphologic parameters assessed by echocardiography and ICG. Patients with CSA had more advanced left ventricular systolic (lower LVEF) and diastolic dysfunction (higher E/e') and larger heart chambers. Likewise, Sin et al. \[[@b23-medscimonit-22-2989]\] found lower LVEF in patients with CSA than with OSA. Javaheri et al. \[[@b1-medscimonit-22-2989]\] found no differences within LVEF between subjects with CSA and OSA, but in relation to those without SDB, they presented lower LVEF \[[@b1-medscimonit-22-2989]\]. Those observations are also convergent with the findings of Oldenburg et al. \[[@b2-medscimonit-22-2989]\].

However, it should be noted that not all researchers observed the relation of CSR with the essential LV dysfunction \[[@b3-medscimonit-22-2989],[@b24-medscimonit-22-2989],[@b29-medscimonit-22-2989]\]. Schulz et al. \[[@b3-medscimonit-22-2989]\] did not show any differences within LVEF among subjects with CSR in comparison to patients with OSA or no SDB. Carmona-Bernali et al. \[[@b24-medscimonit-22-2989]\] did not confirm vital differences in echocardiographic parameters (LVEF, LVDd, LV end-diastolic volume, and end-systolic volume) with respect to CSR.

Impedance cardiography provided more detailed hemodynamic assessment of our patients. The presence of significant CSR was associated with worse hemodynamic parameters: lower SI and CI, and higher SVRI. The obtained results confirmed that CSA/CSR is related with impaired LV function as a blood pump, which partly explains the worse prognosis of such patients \[[@b30-medscimonit-22-2989]\]. Oldenburg et al. \[[@b31-medscimonit-22-2989]\] observed a correlation of AHI with pulmonary capillary wedge pressure (positive), pulmonary artery pressure (positive), and CI (negative) in patients with HF and CSA. Such correlations were not noticed in patients with OSA \[[@b31-medscimonit-22-2989]\]. Giannoni et al. \[[@b32-medscimonit-22-2989]\] reported that CSR may also contribute to increased pulmonary artery pressure and right chamber remodeling.

A significant cardiovascular dysfunction supports the idea of a strong relationship between HF and pathogenesis of CSA. Hyperventilation, hypocapnia, and impaired central regulation of breathing rhythm are strictly related to pulmonary circulatory overload. On the other hand, the studies of Oldenburg et al. \[[@b11-medscimonit-22-2989]\] call attention to another hypothesis, that breathing disorders may be a compensation mechanism. CSR may result in a temporary increase in CI, mainly due to increasing the frequency of HR. Unfortunately, it is detrimental for a damaged heart in long-term prognosis \[[@b11-medscimonit-22-2989]\]. This observation agrees with our observation of higher resting HR in the group of patients with significant CSR.

Predictors of central sleep apnea
---------------------------------

The aggravation of HF symptoms (NYHA class) was revealed to be the only predictor of the occurrence of significant CSR independent of other variables such as permanent AF, the enlargement of LV and RV, LVEF \<35%, E/e' \>15, and SI \<35 ml/m^2^. Other researchers \[[@b23-medscimonit-22-2989],[@b33-medscimonit-22-2989]\] also reported advanced HF, low LVEF, and AF as the predictors of the CSR. They also add hypocapnia (OR 4.33), male sex (OR 3.5), and advanced age \>60 years (OR 2.37) \[[@b23-medscimonit-22-2989]\]. We conclude that the core determinant of CSR is a severe myocardial dysfunction reflecting patient clinical state. However, the assessment of other cardiovascular parameters helps to objectify the reported symptoms and increases the chances to identify patients with CSR, especially in view of the fact that NYHA classification is subjective and can change over time.

Clinical implications and perspectives
--------------------------------------

The clinical importance of CSR in HF patients requires deeper knowledge and further research. As an expression of breathing control system instability, CSR seems to be a reflection of cardiac function, which was confirmed by our results. However, one cannot exclude that CSR is an accompanying disease worsening prognosis, even if activated as a mechanism compensating for co-existing hemodynamic disorders. These doubts indicate the need to consolidate principles of SDB diagnostics and therapy in HF patients. It might be expected that more detailed assessment of the influence of non-invasive ventilation methods (including adaptive servo-ventilation) on hemodynamic disorders related to CSR can contribute to the explanation of discrepancies concerning the prognosis for patients undergoing such therapy \[[@b14-medscimonit-22-2989],[@b17-medscimonit-22-2989],[@b18-medscimonit-22-2989],[@b34-medscimonit-22-2989]--[@b36-medscimonit-22-2989]\].

Limitations
-----------

The basic limitation of our work is the small number of subjects included, which could result in underestimation of differences within studied variables. Moreover, our group consisted mostly of men. Thus, the obtained results should not be extrapolated to women directly. Moreover, we used polygraphy to assess SDB instead of a more detailed method, polysomnography. However, polygraphy meets diagnostic requirements (high sensitivity and specificity) and was also used in many of the cited studies \[[@b2-medscimonit-22-2989],[@b3-medscimonit-22-2989],[@b37-medscimonit-22-2989]\]. The more frequent use of diuretics in patients with significant CSR should be interpreted carefully in view of the fact that we did not provide detailed data regarding classes of diuretics and average doses. We are also aware that more detailed assessment, including of some laboratory tests (e.g., natriuretic peptides) and cardiopulmonary exercise test would complement our methodology.

Conclusions
===========

The extended non-invasive diagnostics confirmed the relationship of CSR with severe cardiovascular alterations and functional state. A detailed hemodynamic assessment may be useful in identification of CSR, but the aggravation of HF symptoms (NYHA class) seems to be the strongest predictor. Changes in hemodynamic profile can be tested as surrogate markers of effectiveness of SDB-specific treatment in future studies.
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###### 

Basic characteristics of the study group (n=161).

  Variable                                    Mean ±SD or n (%)
  ------------------------------------------- ----------------------
  Age (years)                                 64±11
                                              
  Male gender                                 150 (93.2)
                                              
  Height \[cm\]                               173±6.9
                                              
  Weight \[kg\]                               88.6±19.8
                                              
  BMI \[kg/m^2^\]                             29.4±5.9
                                              
  SBP/DBP \[mm Hg\]                           124.2/74.6±17.4/12/0
                                              
  Ischaemic etiology of HF                    106 (65.8)
                                              
  NYHA Class:                                 
   NYHA I                                     14 (8.7)
   NYHA II                                    94 (58.4)
   NYHA III                                   53 (32.9)
                                              
  Hypertension                                140 (87)
                                              
  Atrial fibrillation:                        
   Paroxysmal                                 27 (16.8)
   Permanent                                  52 (32.3)
                                              
  Stimulation in ECG                          27 (16.8)
                                              
  ICD                                         75 (46.6)
                                              
  CRT                                         22 (13.7)
                                              
  Cardiac stimulator different from ICD/CRT   16 (9.9)
                                              
  Medical history:                            
   Stroke/TIA                                 10 (6.2)
   Diabetes                                   55 (34.2)
   COPD                                       23 (14.3)
   eGFR \<60 ml/min/1.73 m^2^                 41 (25.9)
                                              
  Polygraphy                                  
                                              
  AHI \[1/h\]                                 18.4±15.9
                                              
  Mean SaO~2~ \[%\]                           92.8±1.9
                                              
  ODI \[1/h\]                                 18.6±15.4
                                              
  No SDB or AHI \<15/h                        89 (55.3)
                                              
  OSA with AHI ≥15/h                          21 (13)
                                              
  CSA/CSR with AHI ≥15/h                      51 (31.7)
                                              
  Echocardiographic parameters                
   LVEF \[%\]                                 32.8±7.0
   LVDd \[cm\]                                6.43±0.70
   LA \[cm\]                                  4.78±0.57
   RVDd \[cm\]                                3.20±0.53
   E/e'                                       15.4±6.1
                                              
  Haemodynamic parameters (ICG)               
   SI \[ml/m^2^\]                             38.3±8.3
   CI \[l/min/m^2^\]                          2.54±0.52
   SVRI \[dyn·s·cm^−5^·m^2^\]                 2529.3±662.0
   TFC \[1/kOhm\]                             31.2±6.4
                                              
  Pharmacotherapy                             
   B-blockers                                 157 (97.5)
   ACE-I                                      148 (91.9)
   ARB                                        12 (7.5)
   Aldosterone antagonists                    128 (79.5)
   Diuretics                                  144 (89.4)
   Digoxin                                    7 (4.3)
   Amiodarone                                 27 (16.8)

Data presented as means ±SD or as a number (percentage). BMI -- body mass index; SBP -- systolic blood pressure; DBP -- diastolic blood pressure; HF -- heart failure; NYHA -- New York Heart Association; ICD -- implantable cardioverter-defibrilator; CRT -- cardiac resynchronization therapy; TIA -- transient ischemic attack; COPD -- Chronic Obstructive Pulmonary Disease; eGFR -- estimated glomerular filtration rate; AHI -- apnea/hypopnea index; ODI -- oxygen desaturation index; SDB -- sleep-disordered breathing; OSA -- obstructive sleep apnea, CSA -- central sleep apnea, CSR -- Cheyne-Stokes respiration; LVEF -- left ventricular ejection fraction; LVDd -- left ventricular end diastolic diameter; LA -- left atrium; RVDd -- right ventricular end diastolic diameter; E/e' -- the ratio of maximum velocity of the early inflow through the mitral valve and protodiastolic mitral annulus velocity; SI -- stroke index; CI -- cardiac index; SVRI -- systemic vascular resistance index; TFC -- thoracic fluid content; ACE-I -- angiotensin-converting enzyme inhibitor; ARB -- angiotensin receptor blocker.

###### 

Basic comparative characteristics depending on the presence of significant Cheyne-Stokes respiration (CSR).

  Variable                                    Mean ±SD or n (%)   p            
  ------------------------------------------- ------------------- ------------ -------
  Age (years)                                 65±10               63±11        0.251
                                                                               
  Male gender                                 50 (98)             100 (90.9)   0.183
                                                                               
  Height \[cm\]                               174.8±6.7           172.7±7.0    0.073
                                                                               
  Weight \[kg\]                               88.4±20.2           88.7±19.7    0.450
                                                                               
  BMI \[kg/m^2^\]                             29.0±6.5            29.6±5.6     0.962
                                                                               
  HF ischemic etiology                        33 (64.7)           73 (66.4)    0.837
                                                                               
  Hypertension                                43 (84.3)           97 (88.2)    0.497
                                                                               
  Permanent atrial fibrillation               23 (45.1)           29 (26.4)    0.018
                                                                               
  Stimulation in ECG                          9 (17.6)            18 (16.4)    0.839
                                                                               
  ICD                                         30 (58.8)           45 (40.9)    0.034
                                                                               
  CRT                                         7 (13.7)            15 (13.6)    0.988
                                                                               
  Cardiac stimulator different from ICD/CRT   6 (11.8)            10 (9.1)     0.597
                                                                               
  Blood pressure:                                                              
   SBP \[mm Hg\]                              119.5±15.5          126.5±17.9   0.031
   DBP \[mm Hg\]                              75.0±11.7           74.4±12.2    0.674
                                                                               
  Medical history (outside cardiology):                                        
   Stroke/TIA                                 4 (7.8)             6 (5.5)      0.816
   Diabetes                                   17 (33.3)           38 (34.6)    0.880
   CODP                                       3 (5.9)             20 (18.2)    0.067
   GFR \<60 ml/min/1.73 m^2^                  17 (34.7)           24 (22)      0.093
                                                                               
  Pharmacotheraphy:                                                            
   B-blockers                                 50 (98)             107 (97.3)   0.780
   ACE-I                                      46 (90.2)           102 (92.7)   0.812
   ARB                                        5 (9.8)             7 (6.4)      0.652
   Aldosterone antagonists                    41 (80.4)           87 (79.1)    0.849
   Duretics                                   50 (98)             94 (85.5)    0.032
   Digoxin                                    3 (5.9)             4 (3.6)      0.815
   Amiodarone                                 9 (17.7)            18 (16.4)    0.839

Data presented as means ±SD or as a number (percentage). BMI -- body mass index; HF -- heart failure; ICD -- implantable cardioverter-defibrilator; CRT -- cardiac resynchronization therapy; SBP -- systolic blood pressure; DBP -- diastolic blood pressure; TIA -- transient ischemic attack; CODP -- chronic obstructive pulmonary disease; eGFR -- estimated glomerular filtration rate; ACE-I -- angiotensin-converting enzyme inhibitor; ARB -- angiotensin receptor blocker.

###### 

The comparison of polygraphy parameters depending on the presence of significant Cheyne-Stokes respiration (CSR).

  Variable                  Mean ±SD    p           
  ------------------------- ----------- ----------- ----------
  AHI \[1/h\]               33.4±11.7   11.4±12.4   \<0.0001
  AHI obstructive \[1/h\]   4.8±4.4     7.7±10.8    0.480
  AHI central \[1/h\]       28.6±11.0   3.7±4.2     \<0.0001
  ODI \[1/h\]               32.0±13.0   12.7±12.4   \<0.0001
  Minimal SaO2 \[%\]        78.7±6.8    82.6±5.7    \<0.001
  Mean SaO2 \[%\]           92.5±2.0    92.9±1.9    0.274
  Mean desaturation \[%\]   7.4±2.4     5.8±3.6     \<0.0001

Data presented as means ±SD or as a number (percentage). AHI -- apnea/hypopnea index; ODI -- oxygen desaturation index; SaO2 -- arterial oxygen saturation.

###### 

The comparison of echocardiographic parameters depending on the presence of significant Cheyne-Stokes respiration (CSR).

  Variable                      Significant CSR   Without significant CSR   p                                    
  ----------------------------- ----------------- ------------------------- ----------- ----------- ------------ ----------
  LV systolic function          LVEF \[%\]        51                        29.2±7.2    110         34.5±6.4     \<0.0001
  LVEF \<35%                    51                38 (74.5)                 110         51 (46.4)   \<0.001      
  CO \[ml/min\]                 50                5.01±1.76                 110         4.85±0.85   0.917        
  heart chambers (dimensions)   LVDd \[cm\]       51                        6.77±0.64   110         6.27±0.67    \<0.0001
  LVDd ≥6 cm (PLAX)             51                45 (88.2)                 110         82 (74.5)   0.048        
  LA \[cm\]                     51                5.14±0.58                 110         4.61±0.48   \<0.0001     
  LA \>4 cm (PLAX)              51                51 (100)                  110         99 (90)     0.045        
  RVDd \[cm\]                   50                3.40±0.55                 110         3.10±0.50   \<0.001      
  RVDd \>3.3 cm (PLAX)          50                23 (46)                   110         26 (23.6)   0.004        
  LV thickness                  IVSd \[cm\]       50                        1.09±0.16   110         1.06±0.19    0.368
  IVSd \>1.1 cm (PLAX)          50                17 (34)                   110         36 (32.7)   0.874        
  PWd \[cm\]                    50                1.07±0.15                 110         1.05±0.17   0.339        
  LV filling pressure           E/e'              43                        18.2±6.4    94          14.14±5.56   \<0.001
  E/e' \>15                     43                28 (65.1)                 94          35 (37.2)   0.002        

Data presented as means ±SD or as a number (percentage). N-number of patients in whom a given parameter was assessed. CO -- cardiac output; LV -- left ventricle; LVEF -- left ventricular ejection fraction; LVDd -- left ventricular end diastolic diameter; PLAX -- parasternal long axis; LA -- left atrium; RVDd -- right ventricular end diastolic diameter; IVSd -- intraventricular septum in diastole; PWd -- posterior wall in diastole; E/e' -- the ratio of maximum velocity of the early inflow through the mitral valve and protodiastolic mitral annulus velocity.

###### 

The comparison of haemodynamic parameters assessed by impedance cardiography (ICG) depending on the presence of significant Cheyne-Stokes respiration (CSR).

                               Mean ±SD     Statistical significance (p)   
  ---------------------------- ------------ ------------------------------ ---------
  HR \[1/min\]                 67.7±11.5    66.0±9.6                       0.044
  SBP \[mm Hg\]                112.0±13.4   113.9±17.9                     0.545
  DBP \[mm Hg\]                71.6±15.0    70.3±10.8                      0.513
  SI \[ml/m^2^\]               34.8±7.6     39.8±8.1                       \<0.001
  CI \[l/min/m^2^\]            2.37±0.51    2.61±0.52                      0.009
  SVRI \[dyn·s·cm^−5^·m^2^\]   2768±778     2423±576                       0.016
  TFC \[1/kOhm\]               30.6±6.5     31.5±6.4                       0.255
  TFC \>35 1/kOhm              8 (18.2)     20 (19.2)                      0.861
  SI \<35 ml/m^2^              24 (52.2)    28 (26.9)                      0.003
  HR \>70/min                  21 (45.7)    31 (29.8)                      0.066

Reliable measurement of ICG was recorded in 150 patients. Data presented as means ±SD or as a number (percentage).

HR -- heart rate; SBP -- systolic blood pressure; DBP -- diastolic blood pressure; SI -- stroke index; CI -- cardiac index; SVRI -- systemic vascular resistance index; TFC -- thoracic fluid content.

###### 

The results of uni- and multivariate logistic regression (predictors of significant CSR).

  Variable                              Univariate   Multivariate                                 
  ------------------------------------- ------------ -------------- --------- ------ ------------ -------
  NYHA class (per one class)            3.34         1.77--6.30     \<0.001   2.33   1.05--5.19   0.036
  Permanent AF                          2.29         1.14--4.63     0.019     --     --           
  LVEF \< 35%                           3.38         1.61--7.08     0.001     --     --           
  LV enlargement (LVDd ≥6 cm; PLAX)     2.56         0.98--6.70     0.053     --     --           
  RV enlargement (RVDd \>3.3cm; PLAX)   2.75         1.35--5.62     0.005     --     --           
  E/e' \>15                             3.15         1.47--6.73     0.003     --     --           
  SI \<35 ml/m^2^                       2.96         1.43--6.14     0.003     --     --           

NYHA -- New York Heart Association; AF -- atrial fibrillation; LVEF -- left ventricular ejection fraction; LV -- left ventricle; LVDd -- left ventricular end diastolic diameter; PLAX -- parasternal long axis; RV -- right ventricle; RVDd -- right ventricular end diastolic diameter; E/e' -- the ratio of maximum velocity of the early inflow through the mitral valve and protodiastolic mitral annulus velocity; SI -- stroke index.
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